Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells

Early phase clinical trials evaluating CD8+ T cell-eliciting, HER2-derived peptide vaccines administered to HER2-positive breast cancer patients in the adjuvant setting suggest synergy between the vaccines and trastuzumab, the monoclonal antibody targeting the HER2 protein. Among 60 patients enrolle...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Res
Main Authors: Gall, Victor A., Philips, Anne V., Qiao, Na, Clise-Dwyer, Karen, Perakis, Alexander A., Zhang, Mao, Clifton, Guy T., Sukhumalchandra, Pariya, Ma, Qing, Reddy, Sangeetha M., Yu, Dihua, Molldrem, Jeffrey J., Peoples, George E., Alatrash, Gheath, Mittendorf, Elizabeth A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5626640/
https://ncbi.nlm.nih.gov/pubmed/28819024
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-16-2774
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados